Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

By supplying an adequate amount of calcium and vitamin D with the addition of weekly bisphosphonate, the investigators will be able to increase bone mass and decrease the incidence of fragility fractures in these children with muscular dystrophy.

The investigators think this treatment will also decrease the intensity of pain frequently present in these patients and slow the progression of scoliosis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gilles Boire
• Collaborator: Procter and Gamble
• Treatments: Alendronate; Diphosphonates; Risedronic Acid

Criteria

Inclusion Criteria:

• Osteoporosis or osteopenia

• Severe muscular dystrophy or cystic fibrosis

• May use corticosteroids

Exclusion Criteria:

• Inability to consent or to take drugs by mouth